Aclaris Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
Aclaris Therapeutics, Inc. (ACRS) reported Basic Shares Outstanding (Weighted Average) of 142.74 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- Aclaris Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 142.74M shares, a 16.44% increase year-over-year.
- Aclaris Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 128.81M shares, a 5.25% increase year-over-year.
- Aclaris Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 122.67M shares, a 28.53% increase year-over-year.
- Aclaris Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 122.62M shares, a 71.78% increase year-over-year.
- Aclaris Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 122.56M shares, a 58.56% increase from fiscal 2024.
- Aclaris Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 77.30M shares, a 10.73% increase from fiscal 2023.
- Aclaris Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 69.81M shares, a 7.05% increase from fiscal 2022.
- Aclaris Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 65.21M shares, a 14.95% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 142.74M shares 10-Q · filed 2026-08-06 | 135.81M shares 10-Q · filed 2026-08-06 | 131.40M shares derived: average of 3 quarters · filed 2026-08-06 | 129.21M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 128.81M shares 10-Q · filed 2026-05-07 | 125.74M shares derived: average of 2 quarters · filed 2026-05-07 | 124.70M shares derived: average of 3 quarters · filed 2026-05-07 | 124.17M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 122.67M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 122.64M shares derived: average of 2 quarters · filed 2026-02-26 | 122.62M shares derived: average of 3 quarters · filed 2026-08-06 | 122.56M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 122.62M shares 10-Q · filed 2025-11-06 | 122.60M shares derived: average of 2 quarters · filed 2026-08-06 | 122.53M shares 10-Q · filed 2025-11-06 | 115.76M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 122.58M shares 10-Q · filed 2026-08-06 | 122.49M shares 10-Q · filed 2026-08-06 | 113.47M shares derived: average of 3 quarters · filed 2026-08-06 | 102.95M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 122.39M shares 10-Q · filed 2026-05-07 | 108.91M shares derived: average of 2 quarters · filed 2026-05-07 | 96.40M shares derived: average of 3 quarters · filed 2026-05-07 | 90.13M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 95.44M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 83.41M shares derived: average of 2 quarters · filed 2026-02-26 | 79.37M shares derived: average of 3 quarters · filed 2026-02-26 | 77.30M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 71.38M shares 10-Q · filed 2025-11-06 | 71.34M shares derived: average of 2 quarters · filed 2025-11-06 | 71.25M shares 10-Q · filed 2025-11-06 | 71.16M shares derived: average of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | 71.29M shares 10-Q · filed 2025-08-07 | 71.18M shares 10-Q · filed 2025-08-07 | 71.08M shares derived: average of 3 quarters · filed 2025-08-07 | 71.01M shares derived: average of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | 71.07M shares 10-Q · filed 2025-05-08 | 70.98M shares derived: average of 2 quarters · filed 2025-05-08 | 70.92M shares derived: average of 3 quarters · filed 2025-05-08 | 70.85M shares derived: average of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | 70.88M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 70.84M shares derived: average of 2 quarters · filed 2025-02-27 | 70.77M shares derived: average of 3 quarters · filed 2025-02-27 | 69.81M shares 10-K · filed 2025-02-27 |
| 2023-09-30 | 70.81M shares 10-Q · filed 2024-11-06 | 70.72M shares derived: average of 2 quarters · filed 2024-11-06 | 69.45M shares 10-Q · filed 2024-11-06 | 68.75M shares derived: average of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | 70.63M shares 10-Q · filed 2024-08-07 | 68.76M shares 10-Q · filed 2024-08-07 | 68.07M shares derived: average of 3 quarters · filed 2024-08-07 | 67.72M shares derived: average of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | 66.87M shares 10-Q · filed 2024-05-07 | 66.79M shares derived: average of 2 quarters · filed 2024-05-07 | 66.75M shares derived: average of 3 quarters · filed 2024-05-07 | 66.56M shares derived: average of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | 66.70M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 66.69M shares derived: average of 2 quarters · filed 2024-02-27 | 66.46M shares derived: average of 3 quarters · filed 2024-02-27 | 65.21M shares 10-K · filed 2024-02-27 |
| 2022-09-30 | 66.68M shares 10-Q · filed 2023-11-06 | 66.33M shares derived: average of 2 quarters · filed 2023-11-06 | 64.72M shares 10-Q · filed 2023-11-06 | 63.84M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | 65.99M shares 10-Q · filed 2023-08-07 | 63.72M shares 10-Q · filed 2023-08-07 | 62.90M shares derived: average of 3 quarters · filed 2024-02-27 | 62.48M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | 61.43M shares 10-Q · filed 2023-05-08 | 61.35M shares derived: average of 2 quarters · filed 2024-02-27 | 61.31M shares derived: average of 3 quarters · filed 2024-02-27 | 59.47M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | 61.28M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 61.25M shares derived: average of 2 quarters · filed 2024-02-27 | 58.82M shares derived: average of 3 quarters · filed 2024-02-27 | 56.73M shares 10-K · filed 2024-02-27 |
| 2021-09-30 | 61.22M shares 10-Q · filed 2022-11-08 | 57.59M shares derived: average of 2 quarters · filed 2022-11-08 | 55.22M shares 10-Q · filed 2022-11-08 | |
| 2021-06-30 | 53.97M shares 10-Q · filed 2022-08-03 | 52.16M shares 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | 50.34M shares 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | 42.54M shares 10-K · filed 2023-02-23 | |||
| 2019-12-31 | 41.32M shares 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |